We help our partners to accelerate peptide lead optimization and IND-enabling studies: Understand why PK fails in vivo Identify metabolic liabilities at the amino acid level Pinpoint where to modify the peptide Check out the flyer here: #Peptide #DMPK #Biotransformation #DrugMetabolism To view or add a comment, sign in 303 followers
In the brain, the highest densities of GLP-1R are found in the nucleus of the solitary tract, posterior area, interpeduncular nucleus, posterior dorsal nucleus, ventral tegmental area, hypothalamic nuclei, thalamic nuclei, nucleus accumbens, and the lateral septum [5]
The study was published in Nutrients in July 2023
[END CALLOUT BOX] GLP2 Pharmacokinetics & Metabolism Absorption & Distribution Following subcutaneous administration, GLP2 exhibits favorable pharmacokinetic properties enabling once-weekly dosing: Mean absolute bioavailability of approximately 80% after subcutaneous injection Time to maximum plasma concentration (Tmax) ranges from 8 to 72 hours Steady-state plasma concentrations achieved after 4 weeks of once-weekly dosing Mean steady-state volume of distribution approximately 10.3 L, indicating limited tissue distribution The high plasma protein binding to albumin (99%) results from the C20 fatty diacid modification, which provides prolonged systemic exposure and enables sustained therapeutic effects between weekly doses
Why patients choose us: Comprehensive expertise Our team treats the full face, not just one feature